THERAPY WITH AMINEPTINE, A DOPAMINE REUPTAKE INHIBITOR, IN PATIENTS WITH MAJOR DEPRESSION by Channabasavanna, S.M. & Khanna, Sumant
Indian J. Psychiatry., 1997, 39 (2), 147-153 
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ABSTRACT 
The original tricyclic antidepressant drugs are consistently underused in major depression 
because of side effects, delayed onset of action, and potential for overdose. In an open study of 6 
weeks' duration, we studied the efficacy and acceptability of amineptine, a dopamine reuptake 
inhibitor, at fixed dose of 200 mg per day in 50 patients with major depression. 
Intention-to-treat analysis showed a patient response rate of 64% (95% CI 77-50) in HDRS, 62% 
(95% CI 75-48) in MADRS, 46% (95% CI 59-32) in ZUNG scale, 52% (95% CI 66-38) in Social 
Activity scale, and 26% ("95% CI 38-14) in CGI-severity of illness after 7 days treatment. Re-
sponse in CGI-global improvement was 38% (95% CI 51-25), and in CGI-efficacy index 48% (95% 
CI 62-34) after 14 days of treatment. With continued therapy, only CGI-severity of illness showed 
a significant increase in response rate after 42 days. The treatment effect of amineptine was 
reflected in a significant and progressive improvement in all depression, social activity, and CGI 
rating scale scores throughout the study period. Somatic symptoms and side effects assessed by 
AMDP-5 showed significant improvement at each assessment. 
The clinically useful response in depression which occurred by the first week of treatment, favour-
able side effect profile, and the convenience of a fixed dose could make amineptine a suitable first 
line alternative for the treatment of major depression. 
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In the past 30 years there have been 
major changes in the diagnosis and treatment 
of depression (Potter etal., 1991). The original 
tertiary and secondary amine tricyclic 
antidepressant drugs, which have been the 
drugs of choice for major depressive disorders, 
suffer from lack of pharmacologic specificity, 
a delayed onset of action, a potential for fatal 
overdosage, and side effects (Michel et al., 
1993). Epidemiologic studies have constantly 
found that these drugs are underused in those 
who meet the criteria for major depression 
(Shapiro etal., 1983). 
Amongst the newer antidepressant 
agents, amineptine (7-5amino-(10,11-dihydro 
(a,d) dibenzocycloheptenyl) heptanoic acid 
hydrochloride) is a tricyclic antidepressant drug 
that selectively decreases dopamine reupatake 
without affecting other neurotransmitters (Ceci 
et al., 1986). In controlled studies, it is as 
effective as amitriptyline (Van Amerogen, 1979), 
trimipramine (Vauterin and Bazot, 1987), and 
fluoxetine (Dalery et al., 1992). It has a rapid 
onset of action, and is devoid of the 
disadvantages of the original tricyclic 
antidepressant drugs (Deniker et al.,1982). 
These features may favour the use of 
amineptine as a first line drug in the treatment 
of major depression, and improve the 
compliance with treatment of patients seen in 
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everyday clinical practice. 
In a detailed open study we assessed the 
efficacy and acceptability of amineptine in 
Indian patients with major depression (single 
or recurrent episode), and work impairment. 
MATERIAL AND METHOD 
The protocol was approved by the 
institutional ethics committee. To be eligible for 
the study patients had to be between 18 and 65 
years of age, with major depression (single or 
recurrent episode, with or without seasonal pat-
tern or melancholia) diagnosed by DSM IIIR 
criteria (American Psychiatric Association, 
1987), a Montogomery and Asberg depression 
rating scale (MADRS) score of 20, a Hamilton 
depression rating scale (HDRS) score of 18; and 
with work or academic impairment (DSM IIIR 
criteria). Patients were excluded if they had psy-
chotic symptoms, dysthymia during the 
preceding 2 years, a previous history of 
inadequate work or academic performance 
epilepsy, severe hepatic, cardiovascular, or 
neurologic disease, cancer, Huntington's 
chorea or hypersensitvity to amineptine, if they 
were non responders to two antidepressants 
after 4 weeks of treatment with each at full 
therapeutic dose, hospitalised due to suicidal 
risk, under treatment before inclusion for 7 days 
with MAO I, 15 days with reversible MAOI, or 1 
month with fluoxetine, pregnant or breast 
feeding, of child bearing potential without 
contraception, or dependent on alcohol or drugs; 
or if their condition required treatment with ECT. 
After giving their informed consent, 
patients received 200 mg of amineptine 
(survector) daily, in two divided doses at 8 A.M. 
and 12 noon for 6 weeks. Anxiolytic therapy with 
oxazepam was allowed in a dose of less than 
50 mg per day. No other psychotropic 
medication was given. Treatment for associated 
disease, excluding those known to affect 
depression, were recorded at baseline and at 
each assessment. After baseline assessment, 
patients were seen on the 7th, 11th, 14th, and 
21st day and at weekly intervals until the end 
of the 6 weeks study period. 
Assessments were made by trained 
psychiatrists. In most cases each patients's 
condition was evaluated by the same person 
throughout the study. Thirteen clinical variables 
were evaluated : MADRS, HDRS, ZUNG Self 
Rating Depression Scale (ZUNG), Social 
Adjustment Self Reporting Questionnaire 
(SAS), Hamilton Anxiety Rating Scale (HARS), 
Clinical Global Impression (CGI) - severity of 
illness, CGI-global improvement, CGI-efficacy 
index, physical examination, blood pressure, 
heart rate, and weight. The primary outcome 
measures were the MDRS & HDRS. 
The following tests were performed at 
baseline: total haemoglobin, haematocrit, RBC, 
WBC, platelet counts, and WBC differential 
count; total bilirubin, SGPT, gamma GT, SGOT, 
alkaline phosphatase, blood glucouse, and 
serum creatinine; and ECG. Side effects were 
assessed at baseline and at 1st, 2nd, 4th, and 
6th week with the AMDP-5 somatic scale, by 
asking patients about somatic complaints and 
side effects. 
Response to treatment in outcome 
variables was analysed on an intention-to-treat 
basis, and categorical data expressed as a pro-
portion with its standard error. Difference in re-
sponse between assessments was tested by the 
X
2 test. Change '.n outcome variables between 
assessment was compared by the paired T test. 
Significance was defined as a two tailed p value 
of less than 0.05. 
RESULTS 
Fifty consecutive patients who met the 
eligibility criteria entered the study and received 
treatment with amineptine. The baseline 
characteristics of these patients are summarised 
in Table 1. The mean (SD) age was 32.3(10.3) 
years, and the majority were male with major 
depression of moderate severity. Twenty three 
(46%) had recurrent depressive episodes, and 
the mean (SD) duration of illness was 5.4 (3.8) 
months. Among those enrolled,'35 patients 
completed the 6 week regimen of study 
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medication. The timing and reasons of the 15 
patients who withdrew from the study 
medication before 6 weeks are shown in Table 
2. One patient had to be withdrawn because of 
severe anxiety. 
TABLE 1 
BASELINE CHARACTERISTICS Of PATIENTS 
• values are means ±SD. AH other values are numbers of 
patients followed in parentheses by the percentage of the 
group 
The proportion of patients who showed 
improvement in the depression, SAS, and 
CGI-severity of illness scale is shown in Figure 
The intention-to-treat analysis showed that 
TABLE 2 
REASONS FOR EARLY WITHDRAWAL OF PATIENTS 
FROM THE STUDY 
Reason 
Lack of efficacy 
Adverse reaction 
Refusal to continue 
All 
No. of 
patients 
4 
1 
10 
18 
Mean no.* 
of weeks 
3 
1 
3 
-
* After start of etudy treatment 
• Due to severe ewtfety 
F«gtc Pmmm *KM*ig wsmmm* m "tyrmtwu •oca* adjuMmanr and MOT* 
o( 0m* •*•< 1 and B *Mki o* <wtm*< [Manton to Mt baa*) 
Q ata t ipe* fceskqwH Q art* 61 
9*t tapifapal 84% oonMawa Own 
&V«ac*M dflartnea rftMv* lo 1*1 awot 
*»S , HamMon depitsiKin rating •£•>•. IMORS • Uontjnumy ft Aabarg II«IIIIIWI 
rating M-aie ZUNC. - Zung M*-:*.ig rJeptMion teaM SAS • Scowl adjuaknaM 
se« <*pon queswxmait* CGM > CknoA jV**l imtMBwort - M»at*y ol fflrmt 
about half the patients responded after one 
week of treatment and that this response rate 
did not significantly change at 6 weeks, except 
for CGI-severity of illness, in which 
improvement was significantly greater at 6 
weeks compared to the 1st week. The number 
(%, 95 percent confidence interval [CI]) of 
patients with improvement after the first week 
of treatment relative to baseline, was for 
depression, 32 (64, 95% CI 77-50) in HDRS, 
31 (62, 95% CI 75-48) in MADRS, and 23 (46, 
95% CI 59-32) in the ZUNG scale; for social 
activity 26 (52,95% CI 66-38) in the SAS scale; 
and for severity of illness 13 (26, 95% CI 
38-14) in the CGI scale. At the end of 6 weeks 
treatment, scores of less than 8 were observed 
Age (Years) 
Sex (Mela) 
Clinical 
duration of Illness (months) 
recurrent depressive episode* 
weight (kg) 
Wood pressure 
systolic 
diastolic 
Hsemttology 
haemoglobin (gme%) 
tot«IW§C(x1QQ/rnm3) 
platelet count (xlCHVmmS) 
Biochemistry 
total bilirubin (mg%) 
gamma GT (mil/ml) 
SGOT (mU/ml) 
SGPT (mU/ml) 
alkaline phosphatase (mU/ml) 
serum creatinine (mg%) 
fasting blood glucose (mg%) 
32.3*10,3 
34 (W) 
9.4+3.6 
23(49) 
82.2+73 
123+t2.Q 
79.1+9,8 
13,4+1.7 
77,1*18.3 
20,7±7,B 
0.67+0.22 
17.8+6.3 
23.7+8.7 
23.7+10.6 
99.6+26.2 
0.85+0.18 
82.5+11.9 
149 S.M.  CHANNABASAVANNA & SUMANT KHANNA 
TABLE 3 
TREATMENT OUTCOMES WITH AMINEPTINE ON DEPRESSION, SOCIAL ACTIVITY, CLINICAL 
GLOBAL IMPRESSION, SOMATIC, AND ANXIETY SCALES DURING 6 WEEKS OF STUDY 
Outcome 
Depression 
HDRS 
MADRS 
ZUNG 
Social adjustment 
SAS 
Clinicl global impression 
Severity of illness 
Global improvement + 
Efficacy index + 
Somatic symptoms and side effects 
AMDP-5 
Anxiety 
HARS 
Baseline 
score 
24.3+5 7 
32.7+5.5 
58.2+6.4 
78.2+24.0 
3.6+0.7 
2.3+0.1 
22.6+2.6 
17.2+5.6 
14.0+5.1 
Reduction in score from baseline after treatment (mean+S.D.) 
1st week 2nd week 3rd week 6th week 
(n=45) (n=42) (n=41) (n=35) 
4.3+6.3* 95+7.5* 
6.9+9.5' 11.8+11.1* 
4.6+8.2* 9.7+12.3* 
6.4+18.0* 13.1+18.1* 
0.3+0.7* 0.8+1.0* 
0.5+1.0* 
6.8+9.4* 
3.4+6.2* 6.4+6.3* 
-
12.4+8.0* 
16.5+11.5* 
13.5+13.4* 
18:6+1&\2* 
1.3+1.2* 
0.8+1.0* 
9.5+10.0* 
-
-
15.9+9.1* 
22.4+9.9* 
21.8+15.2* 
21.3+224* 
2.0+1.4* 
1.1+1.4* 
123+10.7* 
11.0±6.2* 
7.8+7.3 
* Reduction in score is significant as compared to score + Baseline assessment after 1 st week of treatment 
at previous assessment 
HDRS= Hamilton depression rating scale; MADRS-Montgomery J Asberg depression rating ; ZUNG-Zung self-rating 
depression scale; SAS-social adjustment self report questionnaire; HARS=Hamilton anxeity rating scale 
in 23 (46, 95% CI 59.8-32.0) on HDRS and in 
19 (38, 95% CI 51.5-24.5) on MADRS scales. 
Significant increase in improvement relative to 
that at the 1st week, was observed only in 
severity of illness, in 17 (34%,p<0.001) 
patients on the CGI scale. The number 
(percent, 95% CI) of patients who responded 
after 2 weeks treatment, relative to baseline, in 
global improvement was 19 (38, 95% CI 
51-25), and in efficacy index 24 (48, 95% CI 
62-34) on the CGI scale, with no further 
significant change upto 6 weeks. The nurnber 
(percent, 95% CI) of patients with improvement 
in anxiety after 6 weeks treatment compared to 
baseline was 29 (58, 95% CI 72-44) on the 
HARS. 
There was significant treatment effect 
with amineptine in all clinical outcome 
measures at each assessment, as summarised 
in Table 3. After 1 week of treatment, 
compared to baseline, mean (SD) improvement 
in scores was 4.3 (6.3, p<0.001) in HDRS, 6.9 
(9.5, p<0.001) in MADRS, 4.6 (8.2, p<0.001) 
in ZUNG scale, 6.4 (17.6, p<0.01) in SAS, and 
0.3 (0.7, p<0.01) in CGI-severity of illness. Be-
tween the 1st and 2nd week of treatment, mean 
(SD) improvement was 4.0 (5.2, p<0.001) in 
HDRS, 5.4 (6.7, p<0.001) in MADRS, 4.0 (7.8, 
p<0.001) in ZUNG scale, 7.7 (15.3, p<0.001) in 
SAS, and 0.5 (0.9, p<0.002) in the CGI-sever-
ity of illness. The mean (SD) improvement in 
scores between the 2nd and 3rd week of 
treatment was 3.0 (4.91, p<0.001) in HDRS, 4.6 
(6.84, p<0.001) in MADRS, 4.0 (7.8, p<0.01)in 
ZUNG scale. 5.6 (11.69, p<0.01) in SAS, 0.5 
(0.7, p<0.00l) in the CGI -severity of illness and 
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0.39 (0.7, p<0.001) in CGI-gtobal improvement. 
Between the 3rd and 6th week of treatment 
mean (SD) improvement in scores was 3.5 (4.1, 
p<0.001) in HDRS, 6.1 (1.9, p<0.001) in 
MADRS, 2.4 (6.3-, p<0.05) in ZUNG scale, 2.7 
(11.3, p<0.01) in SAS, and'0.7 (0.7, p<0.01) in 
CGI-severity of illness. There was no signifi-
cant change in CGI-global improvement. HARS 
scores showed a mean (SD) improvement of 
7.71 (7.28, p<0.001) after 6 weeks treatment 
relative to baseline. 
The effect of treatment on side effects 
assessed by the AMDP-5 scale and the 
efficacy of amineptine assessed by the CGI-
efficacy index are shown in Table 3. Mean (SD) 
scores in AMDP-5 improved by 3.38 (6.2, 
p<0.001) between baseline and the 1st week, 
by 2.83 (6.5, p<0.01) between the 1st and 2nd 
week, by 3.6 (5.54, p<0.01) between the 2nd 
and 4th week, and did not change signiificantly 
between the 4th and 6th week of treatment. The 
mean (SD) scores in CGI-efficacy index im-
proved by 2.6 (10.07, p<0.001) between the 1st 
and 2nd week, by 2.6 (6.4, p<0.01) between 
the 2nd and 3rd week, and by 2.8 (5.6, p<0.01) 
between the 3rd and 6th week. There were no 
significant changes in heart rate or blood 
pressure after 6 week of treatment compared 
to the baseline. 
DISCUSSION 
Patients with moderate to severe major 
depression and work or academic impairement 
had clinically significant improvement when 
treated with amineptine. As shown in Figure and 
Table 3, the benefits were consistent for all clini-
cal outcomes which included the depression 
rating scales (HDRS, MADRS and ZUNG), so-
cial adjustment scale (SAS), clinical global 
improvession scales (severity of illness, global 
improvement, and efficacy index), somatic 
symptoms and side effects scale (AMDP-5), and 
anxiety scale (HARS). The intention-to-treat 
analysis (Figure) showed a patient response rate 
in depression of 60-70%, to fixed dose of 
amineptine (200mg per day), which occured 
within the 1st week, which increased 
significantly to about 60% by the 6th week. 
The extent of improvement with 
amineptine (Table 3) is progressive over time 
in all depression, social adjustment, and CGI 
scales, with significant reduction in scores 
occurring at each assessment compared to the 
previous one, from the 1st to the 6th week of 
treatment. Somatic symptoms and side effects 
related to sleep, gastrointestinal, caridovascular, 
neurologic and autonomic systems, assessed 
by the AMDP-5 scale (Table 3) did not increase 
but showed a significant decrease at each 
assessment from the 1st to the 4th week of 
treatment. The balance between therapeutic 
benefits and side effects with amineptine 
therapy assessed by the CGI-efficacy index 
(table 3) also showed significant increase in 
therapeutic benefits at each assessment from 
the 2nd to 6th week. Anxiety assessed by the 
HARS (Table 3) improved significantly after 6 
weeks of treatment. The lack of effect of 
amineptine on heart rate and blood pressure is 
consistent with previous studies (Boral et at., 
1989). 
In major depression, the traditional drugs 
(such as imipramine and amitriptyline) continue 
to be the treatment of choice (Potter et al., 
1991). However, there are several problems 
related to their use. With standard treatments, 
even when pushed to deliver the equivalent of 
200-300 mg imipramine per day, only 70-80% 
of patients show clincial response (Michel et al., 
1993). In those who respond only 50-60% show 
clinical improvement before 4 weeks of 
treatment (Potter et al., 1991). The 
anticholinergic, antihistaminergic, sedative, 
orthostatic hypotensive, and cardiotoxic 
properties related to their use (IT Prichard et 
al., 1978), and potential for fatal overdose (Milne 
et al., 1993) result in about 30% of patients not 
complying with treatment at all, and about 25% 
being treated with inadequate doses (Harrison, 
1994). 
Studies in depression, Parkinson's 
disease and animal models of depression, 
suggest an aetiologic role of dopamine 
deficiency in major depression (Kapoor and 
Mann, 1992). Amineptine, a recent antidepres-
sant drug in India, selectively inhibits dopamine 
reuptake without affecting other 
neurotransmitters (Ceci et al., 1986). In 
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controlled and large open studies, its 
antidepressant efficacy is equal to traditional 
tricyclic drugs (Van Amerongen, 1979; Deniker 
et al., 1982: Vauterin and Bazat., 1987) and 
serotonin reuptake inhibitors (Dalery et al., 
1992). The frequency of side effects is low, with 
a withdrawal rate of 3.5% due to 
anxiety, nausea, and palpitations, and no 
withdrawals due to unacceptable anticholiner-
gic, antihistaminergic, orthostatic or cardiotoxic 
event (Deniker etal., 1982), even in the elderly 
(Reignier, 1983). It has no effect on liver and 
renal function or body weight (Boral et al., 1989). 
Our protocol which included 3 different 
measures each for depression, and clinical 
global impression, and one measure each of 
social adjustment, anxiety, somatic symptoms 
and side effects, provides a detailed evalua-
tion of the efficacy and safety of amineptine, 
although the absence of a control group is a 
limitation. From our results, the usefulness of 
therapy with amineptine can be evaulated from 
different perspectives. Symptoms of major 
depression improved rapidly in a high 
proportion of patients; the dosage was fixed 
requiring no titration reflecting ease of prescrip-
tion especially for out patients and general 
practioners: and social adjustment improved 
with depression which may allow patients an 
early resumption of work and a normal life style. 
The withdrawal rate was low, major side effects, 
adverse haemodynamic events, and cardiotox-
icity were absent, and somatic symptoms 
improved. This could result in better patient 
compliance. Many believe that an increased 
compliance of just 6% represents a recovery of 
4-5% of depressed patients (Harrison, 1994). 
In the short term amineptine may be suitable 
as a first line drug for major depression seen in 
every day clinical practice. Long term follow up 
is required to assess whether benefits are 
maintained, and if toxicity is increased. 
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